INmune Bio
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell INmune Bio and other ETFs, options, and stocks.About INMB
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate.
CEODavid J. Moss
CEODavid J. Moss
Employees22
Employees22
HeadquartersBoca Raton, Florida
HeadquartersBoca Raton, Florida
Founded2015
Founded2015
Employees22
Employees22
INMB Key Statistics
Market cap50.91M
Market cap50.91M
Price-Earnings ratio-0.77
Price-Earnings ratio-0.77
Dividend yield—
Dividend yield—
Average volume817.41K
Average volume817.41K
High today$2.02
High today$2.02
Low today$1.91
Low today$1.91
Open price$1.97
Open price$1.97
Volume578.78K
Volume578.78K
52 Week high$11.64
52 Week high$11.64
52 Week low$1.71
52 Week low$1.71
INMB News
TipRanks 3d
INmune Bio completes first commercial manufacturing run of CORDStromINmune Bio (INMB) announced the successful completion of its first full-scale pilot commercial manufacturing run of CORDStrom, an off-the-shelf, allogeneic, umb...
Analyst ratings
50%
of 6 ratingsBuy
50%
Hold
50%
Sell
0%
People also own
Based on the portfolios of people who own INMB. This list is generated using Robinhood data, and it’s not a recommendation.